Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick Acquires 1,514 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE:CRL opened at $163.11 on Friday. The company has a market capitalization of $8.34 billion, a price-to-earnings ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $172.84 and a 200 day moving average price of $188.37. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.46 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.41 EPS for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after acquiring an additional 60,497 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after buying an additional 335,658 shares in the last quarter. State Street Corp grew its position in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after buying an additional 47,221 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock worth $227,042,000 after buying an additional 14,787 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRL has been the topic of several analyst reports. Evercore ISI lifted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Bank of America reduced their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Morgan Stanley reduced their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $195.71.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).